Cargando…

Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial

Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez, Esther, Manzano, Susana, Schlembach, Dietmar, Arciszewski, Krzysztof, Martin, Rocio, Ben Amor, Kaouther, Roelofs, Mieke, Knol, Jan, Rodríguez, Juan Miguel, Abou-Dakn, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469334/
https://www.ncbi.nlm.nih.gov/pubmed/34576828
http://dx.doi.org/10.3390/microorganisms9091933
_version_ 1784573904497410048
author Jiménez, Esther
Manzano, Susana
Schlembach, Dietmar
Arciszewski, Krzysztof
Martin, Rocio
Ben Amor, Kaouther
Roelofs, Mieke
Knol, Jan
Rodríguez, Juan Miguel
Abou-Dakn, Michael
author_facet Jiménez, Esther
Manzano, Susana
Schlembach, Dietmar
Arciszewski, Krzysztof
Martin, Rocio
Ben Amor, Kaouther
Roelofs, Mieke
Knol, Jan
Rodríguez, Juan Miguel
Abou-Dakn, Michael
author_sort Jiménez, Esther
collection PubMed
description Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (p = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; p = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of L. salivarius PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding.
format Online
Article
Text
id pubmed-8469334
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84693342021-09-27 Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial Jiménez, Esther Manzano, Susana Schlembach, Dietmar Arciszewski, Krzysztof Martin, Rocio Ben Amor, Kaouther Roelofs, Mieke Knol, Jan Rodríguez, Juan Miguel Abou-Dakn, Michael Microorganisms Article Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (p = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; p = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of L. salivarius PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding. MDPI 2021-09-11 /pmc/articles/PMC8469334/ /pubmed/34576828 http://dx.doi.org/10.3390/microorganisms9091933 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jiménez, Esther
Manzano, Susana
Schlembach, Dietmar
Arciszewski, Krzysztof
Martin, Rocio
Ben Amor, Kaouther
Roelofs, Mieke
Knol, Jan
Rodríguez, Juan Miguel
Abou-Dakn, Michael
Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title_full Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title_fullStr Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title_full_unstemmed Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title_short Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial
title_sort ligilactobacillus salivarius ps2 supplementation during pregnancy and lactation prevents mastitis: a randomised controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469334/
https://www.ncbi.nlm.nih.gov/pubmed/34576828
http://dx.doi.org/10.3390/microorganisms9091933
work_keys_str_mv AT jimenezesther ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT manzanosusana ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT schlembachdietmar ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT arciszewskikrzysztof ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT martinrocio ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT benamorkaouther ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT roelofsmieke ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT knoljan ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT rodriguezjuanmiguel ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT aboudaknmichael ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial
AT ligilactobacillussalivariusps2supplementationduringpregnancyandlactationpreventsmastitisarandomisedcontrolledtrial